{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:01:05Z","timestamp":1792166465370,"version":"4.4.0"},"reference-count":190,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"vor","delay-in-days":371,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK098655"],"award-info":[{"award-number":["DK098655"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AG06791"],"award-info":[{"award-number":["R01AG06791"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Metabolism"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.cmet.2023.01.006","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T10:52:55Z","timestamp":1675767175000},"page":"236-252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":284,"title":["The role of hepatokines in NAFLD"],"prefix":"10.1016","volume":"35","author":[{"given":"Norbert","family":"Stefan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fritz","family":"Schick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas L.","family":"Birkenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Ulrich","family":"H\u00e4ring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2166-508X","authenticated-orcid":false,"given":"Morris F.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmet.2023.01.006_bib1","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.cmet.2023.01.006_bib2","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.cmet.2022.05.003","article-title":"Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer","volume":"34","author":"Huang","year":"2022","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2023.01.006_bib3","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cmet.2023.01.006_bib4","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/gutjnl-2020-322572","article-title":"Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals","volume":"70","author":"Mantovani","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.cmet.2023.01.006_bib5","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","article-title":"Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis","volume":"6","author":"Mantovani","year":"2021","journal-title":"Lancet. Gastroenterol. Hepatol."},{"key":"10.1016\/j.cmet.2023.01.006_bib6","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/gutjnl-2022-327672","article-title":"Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals","volume":"72","author":"Mantovani","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.cmet.2023.01.006_bib7","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/gutjnl-2021-324191","article-title":"Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies","volume":"71","author":"Mantovani","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.cmet.2023.01.006_bib8","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","article-title":"Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis","volume":"10","author":"Anstee","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.cmet.2023.01.006_bib9","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2017.09.021","article-title":"Hypertension, diabetes, atherosclerosis and NASH: cause or consequence?","volume":"68","author":"Lonardo","year":"2018","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.cmet.2023.01.006_bib10","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1056\/NEJMcibr1910023","article-title":"Nonalcoholic fatty liver disease, insulin resistance, and ceramides","volume":"381","author":"Samuel","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cmet.2023.01.006_bib11","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMra1011035","article-title":"Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease","volume":"371","author":"Shulman","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cmet.2023.01.006_bib12","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S2213-8587(18)30154-2","article-title":"Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies","volume":"7","author":"Stefan","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.cmet.2023.01.006_bib13","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41575-021-00448-y","article-title":"The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments","volume":"18","author":"Targher","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.cmet.2023.01.006_bib14","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cmet.2023.01.006_bib15","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S2213-8587(16)00082-6","article-title":"Phenotypes of prediabetes and stratification of cardiometabolic risk","volume":"4","author":"Stefan","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.cmet.2023.01.006_bib16","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.cmet.2017.07.008","article-title":"Causes, characteristics, and consequences of metabolically unhealthy normal weight in humans","volume":"26","author":"Stefan","year":"2017","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2023.01.006_bib17","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.cmet.2023.01.006_bib18","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S2213-8587(22)00003-1","article-title":"A global view of the interplay between non-alcoholic fatty liver disease and diabetes","volume":"10","author":"Stefan","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.cmet.2023.01.006_bib19","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(17)32366-8","article-title":"Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"390","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.cmet.2023.01.006_bib20","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1016\/S2213-8587(18)30150-5","article-title":"Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment","volume":"6","author":"Pearson-Stuttard","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.cmet.2023.01.006_bib21","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cmet.2023.01.006_bib22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cld.2017.08.003","article-title":"The natural history of nonalcoholic fatty liver disease-an evolving view","volume":"22","author":"Lindenmeyer","year":"2018","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.cmet.2023.01.006_bib23","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.cmet.2023.01.006_bib24","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1053\/j.gastro.2012.02.003","article-title":"Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications","volume":"142","author":"Cusi","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cmet.2023.01.006_bib25","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1002\/hep.25539","article-title":"Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease","volume":"55","author":"Lomonaco","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.cmet.2023.01.006_bib26","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/hep.26672","article-title":"Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes","volume":"59","author":"Birkenfeld","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.cmet.2023.01.006_bib27","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41586-019-1797-8","article-title":"The integrative biology of type 2 diabetes","volume":"576","author":"Roden","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.cmet.2023.01.006_bib28","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1172\/JCI134165","article-title":"Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease","volume":"130","author":"Smith","year":"2020","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.cmet.2023.01.006_bib29","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2337\/dc20-1644","article-title":"Hepatic insulin resistance is not pathway selective in humans with nonalcoholic fatty liver disease","volume":"44","author":"Ter Horst","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cmet.2023.01.006_bib30","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/nature05488","article-title":"Abdominal obesity and metabolic syndrome","volume":"444","author":"Despr\u00e9s","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.cmet.2023.01.006_bib31","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.cmet.2013.03.008","article-title":"Mechanisms and metabolic implications of regional differences among fat depots","volume":"17","author":"Tchkonia","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2023.01.006_bib32","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nrendo.2014.185","article-title":"Biology of upper-body and lower-body adipose tissue--link to whole-body phenotypes","volume":"11","author":"Karpe","year":"2015","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.cmet.2023.01.006_bib33","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/joim.12540","article-title":"Adipose tissue regulates insulin sensitivity: role of adipogenesis, de novo lipogenesis and novel lipids","volume":"280","author":"Smith","year":"2016","journal-title":"J.\u00a0Intern. Med."},{"key":"10.1016\/j.cmet.2023.01.006_bib34","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41580-018-0093-z","article-title":"Adipogenesis and metabolic health","volume":"20","author":"Ghaben","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.cmet.2023.01.006_bib35","doi-asserted-by":"crossref","first-page":"3990","DOI":"10.1172\/JCI129187","article-title":"Altered adipose tissue and adipocyte function in the pathogenesis of metabolic syndrome","volume":"129","author":"Kahn","year":"2019","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.cmet.2023.01.006_bib36","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S2213-8587(20)30110-8","article-title":"Causes, consequences, and treatment of metabolically unhealthy fat distribution","volume":"8","author":"Stefan","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.cmet.2023.01.006_bib37","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2337\/db18-0708","article-title":"Genome-wide and abdominal MRI data provide evidence that a genetically determined favorable adiposity phenotype is characterized by lower ectopic liver fat and lower risk of type 2 diabetes, heart disease, and hypertension","volume":"68","author":"Ji","year":"2019","journal-title":"Diabetes"},{"key":"10.1016\/j.cmet.2023.01.006_bib38","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1172\/JCI129190","article-title":"What lipodystrophies teach us about the metabolic syndrome","volume":"129","author":"Mann","year":"2019","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.cmet.2023.01.006_bib39","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.ecl.2016.06.012","article-title":"Lipodystrophy syndromes","volume":"45","author":"Hussain","year":"2016","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"10.1016\/j.cmet.2023.01.006_bib40","doi-asserted-by":"crossref","first-page":"836","DOI":"10.7326\/L19-0635","article-title":"Lipodystrophic nonalcoholic fatty liver disease induced by immune checkpoint blockade","volume":"172","author":"Eigentler","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.cmet.2023.01.006_bib41","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41574-022-00641-2","article-title":"Exerkines in health, resilience and disease","volume":"18","author":"Chow","year":"2022","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.cmet.2023.01.006_bib42","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1210\/endrev\/bnaa016","article-title":"Muscle-organ crosstalk: the emerging roles of myokines","volume":"41","author":"Severinsen","year":"2020","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.cmet.2023.01.006_bib43","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41574-019-0156-z","article-title":"Gut microbial metabolites in obesity, NAFLD and T2DM","volume":"15","author":"Canfora","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.cmet.2023.01.006_bib44","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1038\/s41591-022-02016-6","article-title":"Microbiome-derived ethanol in nonalcoholic fatty liver disease","volume":"28","author":"Meijnikman","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.cmet.2023.01.006_bib45","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S2468-1253(20)30252-1","article-title":"A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study","volume":"5","author":"Harrison","year":"2020","journal-title":"Lancet. Gastroenterol. Hepatol."},{"key":"10.1016\/j.cmet.2023.01.006_bib46","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.3390\/cells11162581","article-title":"The stress-responsive microRNA-34a alters insulin signaling and actions in adipocytes through induction of the tyrosine phosphatase PTP1B","volume":"11","author":"Cornejo","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.cmet.2023.01.006_bib47","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.cmet.2017.04.001","article-title":"Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease","volume":"25","author":"Loomba","year":"2017","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2023.01.006_bib48","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.cmet.2020.06.005","article-title":"A universal gut-microbiome-derived signature predicts cirrhosis","volume":"32","author":"Oh","year":"2020","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2023.01.006_bib49","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.2337\/db11-0231","article-title":"The metabolically benign and malignant fatty liver","volume":"60","author":"Stefan","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.cmet.2023.01.006_bib50","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00125-019-05024-3","article-title":"Non-alcoholic fatty liver disease and cardiovascular disease: assessing the evidence for causality","volume":"63","author":"Brouwers","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.cmet.2023.01.006_bib51","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cmet.2019.12.002","article-title":"Leveraging human genetics to identify potential new treatments for fatty liver disease","volume":"31","author":"Romeo","year":"2020","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2023.01.006_bib52","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1073\/pnas.0630588100","article-title":"Triglyceride accumulation protects against fatty acid-induced lipotoxicity","volume":"100","author":"Listenberger","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cmet.2023.01.006_bib53","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1126\/science.1123965","article-title":"Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase","volume":"312","author":"Haemmerle","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.cmet.2023.01.006_bib54","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/nm.2744","article-title":"Hepatic Hdac3 promotes gluconeogenesis by repressing lipid synthesis and sequestration","volume":"18","author":"Sun","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.cmet.2023.01.006_bib55","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jhep.2020.03.006","article-title":"Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping","volume":"73","author":"Liu","year":"2020","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.cmet.2023.01.006_bib56","doi-asserted-by":"crossref","first-page":"460","DOI":"10.2337\/dc21-1262","article-title":"Estimating the effect of liver and pancreas volume and fat content on risk of diabetes: a mendelian randomization study","volume":"45","author":"Martin","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cmet.2023.01.006_bib57","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1038\/s41588-022-01199-5","article-title":"Multiomics study of nonalcoholic fatty liver disease","volume":"54","author":"Sveinbjornsson","year":"2022","journal-title":"Nat. Genet."},{"key":"10.1016\/j.cmet.2023.01.006_bib58","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1053\/j.gastro.2020.12.023","article-title":"Exome-wide association study on alanine aminotransferase identifies sequence variants in the GPAM and APOE associated with fatty liver disease","volume":"160","author":"Jamialahmadi","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cmet.2023.01.006_bib59","series-title":"Practical Guide to Life Science Databases","first-page":"27","article-title":"The genecards suite","author":"Safran","year":"2021"},{"key":"10.1016\/j.cmet.2023.01.006_bib60","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jhep.2016.04.005","article-title":"Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications","volume":"65","author":"Francque","year":"2016","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.cmet.2023.01.006_bib61","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrendo.2017.173","article-title":"Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus","volume":"14","author":"Targher","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.cmet.2023.01.006_bib62","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S2468-1253(21)00020-0","article-title":"Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach","volume":"6","author":"Targher","year":"2021","journal-title":"Lancet. Gastroenterol. Hepatol."},{"key":"10.1016\/j.cmet.2023.01.006_bib63","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/s41467-020-14450-6","article-title":"Liver governs adipose remodelling via extracellular vesicles in response to lipid overload","volume":"11","author":"Zhao","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cmet.2023.01.006_bib64","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1053\/j.gastro.2017.08.013","article-title":"Metabolic circuit involving free fatty acids, microRNA 122, and triglyceride synthesis in liver and muscle tissues","volume":"153","author":"Chai","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cmet.2023.01.006_bib65","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1042\/CS20190558","article-title":"Exosomal microRNA-122 mediates obesity-related cardiomyopathy through suppressing mitochondrial ADP-ribosylation factor-like 2","volume":"133","author":"Wang","year":"2019","journal-title":"Clin. Sci."},{"key":"10.1016\/j.cmet.2023.01.006_bib66","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1210\/er.2008-0009","article-title":"Causes and metabolic consequences of fatty liver","volume":"29","author":"Stefan","year":"2008","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.cmet.2023.01.006_bib67","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nrendo.2012.258","article-title":"The role of hepatokines in metabolism","volume":"9","author":"Stefan","year":"2013","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.cmet.2023.01.006_bib68","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s00125-015-3634-4","article-title":"Hepatokines: unlocking the multi-organ network in metabolic diseases","volume":"58","author":"Iroz","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.cmet.2023.01.006_bib69","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrendo.2017.56","article-title":"Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance","volume":"13","author":"Meex","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.cmet.2023.01.006_bib70","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1210\/er.2019-00034","article-title":"The liver as an endocrine organ-linking NAFLD and insulin resistance","volume":"40","author":"Watt","year":"2019","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.cmet.2023.01.006_bib71","doi-asserted-by":"crossref","first-page":"101138","DOI":"10.1016\/j.molmet.2020.101138","article-title":"Hepatokines and metabolism: deciphering communication from the liver","volume":"44","author":"Jensen-Cody","year":"2021","journal-title":"Mol. Metab."},{"key":"10.1016\/j.cmet.2023.01.006_bib72","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.4254\/wjh.v13.i11.1611","article-title":"Newly discovered endocrine functions of the liver","volume":"13","author":"Rhyu","year":"2021","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.cmet.2023.01.006_bib73","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3390\/ijms23010498","article-title":"Non-alcoholic steatohepatitis (NASH) and organokines: what is now and what will be in the future","volume":"23","author":"Santos","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cmet.2023.01.006_bib89","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1001\/jama.300.2.182","article-title":"Fetuin-A and incident diabetes mellitus in older persons","volume":"300","author":"Ix","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.cmet.2023.01.006_bib90","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.2337\/db08-0538","article-title":"Plasma fetuin-A levels and the risk of type 2 diabetes","volume":"57","author":"Stefan","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.cmet.2023.01.006_bib91","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1161\/CIRCULATIONAHA.111.072751","article-title":"Association of fetuin-a with incident diabetes mellitus in community-living older adults: the cardiovascular health study","volume":"125","author":"Ix","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.cmet.2023.01.006_bib92","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.2337\/db17-1268","article-title":"Circulating fetuin-A and risk of type 2 diabetes: a mendelian randomization analysis","volume":"67","author":"Kr\u00f6ger","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.cmet.2023.01.006_bib93","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1161\/CIRCULATIONAHA.108.814418","article-title":"Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke","volume":"118","author":"Weikert","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.cmet.2023.01.006_bib95","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.2337\/dc12-2323","article-title":"Genetically elevated fetuin-A levels, fasting glucose levels, and risk of type 2 diabetes: the cardiovascular health study","volume":"36","author":"Jensen","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cmet.2023.01.006_bib94","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1161\/CIRCGENETICS.109.870410","article-title":"Association of AHSG gene polymorphisms with fetuin-A plasma levels and cardiovascular diseases in the EPIC-Potsdam study","volume":"2","author":"Fisher","year":"2009","journal-title":"Circ. Cardiovasc. Genet."},{"key":"10.1016\/j.cmet.2023.01.006_bib96","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.atherosclerosis.2015.08.031","article-title":"Fetuin-A and risk of coronary heart disease: a Mendelian randomization analysis and a pooled analysis of AHSG genetic variants in 7 prospective studies","volume":"243","author":"Laugsand","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cmet.2023.01.006_bib103","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1701329","article-title":"Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides","volume":"377","author":"Graham","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cmet.2023.01.006_bib104","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1093\/eurheartj\/ehaa689","article-title":"Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia","volume":"41","author":"Gaudet","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.cmet.2023.01.006_bib189","doi-asserted-by":"crossref","first-page":"e92238","DOI":"10.1371\/journal.pone.0092238","article-title":"Impact of the adipokine adiponectin and the hepatokine fetuin-A on the development of type 2 diabetes: prospective cohort- and cross-sectional phenotyping studies","volume":"9","author":"Stefan","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cmet.2023.01.006_bib195","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/ajcn\/nqz076","article-title":"Genome-wide association study of breakfast skipping links clock regulation with food timing","volume":"110","author":"Dashti","year":"2019","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.cmet.2023.01.006_bib107","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.cmet.2013.08.005","article-title":"The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes","volume":"18","author":"Gaich","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2023.01.006_bib108","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.cmet.2016.02.001","article-title":"A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects","volume":"23","author":"Talukdar","year":"2016","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2023.01.006_bib110","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial","volume":"392","author":"Sanyal","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cmet.2023.01.006_bib111","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1210\/clinem\/dgab624","article-title":"LLF580, an FGF21 analog, reduces triglycerides and hepatic fat in obese adults with modest hypertriglyceridemia","volume":"107","author":"Rader","year":"2022","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.cmet.2023.01.006_bib126","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1056\/NEJMoa0804381","article-title":"Sex hormone-binding globulin and risk of type 2 diabetes in women and men","volume":"361","author":"Ding","year":"2009","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cmet.2023.01.006_bib127","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/hmg\/ddp522","article-title":"Genetic evidence that raised sex hormone binding globulin (SHBG) levels reduce the risk of type 2 diabetes","volume":"19","author":"Perry","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.cmet.2023.01.006_bib128","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1161\/01.CIR.0000157697.54255.CE","article-title":"Sex-hormone-binding globulin and the free androgen index are related to cardiovascular risk factors in multiethnic premenopausal and perimenopausal women enrolled in the Study of Women Across the Nation (SWAN)","volume":"111","author":"Sutton-Tyrrell","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.cmet.2023.01.006_bib137","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.gene.2013.10.035","article-title":"Genetic variants in selenoprotein P plasma 1 gene (SEPP1) are associated with fasting insulin and first phase insulin response in Hispanics","volume":"534","author":"Hellwege","year":"2014","journal-title":"Gene"},{"key":"10.1016\/j.cmet.2023.01.006_bib156","doi-asserted-by":"crossref","first-page":"6486","DOI":"10.1038\/s41467-021-26536-w","article-title":"Elevated circulating follistatin associates with an increased risk of type 2 diabetes","volume":"12","author":"Wu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cmet.2023.01.006_bib74","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1042\/BJ20100330","article-title":"NF-kappaB mediates lipid-induced fetuin-A expression in hepatocytes that impairs adipocyte function effecting insulin resistance","volume":"429","author":"Dasgupta","year":"2010","journal-title":"Biochem. J."},{"key":"10.1016\/j.cmet.2023.01.006_bib75","doi-asserted-by":"crossref","first-page":"448","DOI":"10.5551\/jat.No950","article-title":"High glucose induces transactivation of the alpha2-HS glycoprotein gene through the ERK1\/2 signaling pathway","volume":"16","author":"Takata","year":"2009","journal-title":"J.\u00a0Atheroscler. Thromb."},{"key":"10.1016\/j.cmet.2023.01.006_bib76","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/0092-8674(89)90098-6","article-title":"Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity","volume":"58","author":"Auberger","year":"1989","journal-title":"Cell"},{"key":"10.1016\/j.cmet.2023.01.006_bib77","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1038\/nm.2851","article-title":"Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance","volume":"18","author":"Pal","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.cmet.2023.01.006_bib78","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/nm.2869","article-title":"Fetuin-A: the missing link in lipid-induced inflammation","volume":"18","author":"Heinrichsdorff","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.cmet.2023.01.006_bib79","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1007\/s00125-017-4385-1","article-title":"Metabolic crosstalk between fatty pancreas and fatty liver: effects on local inflammation and insulin secretion","volume":"60","author":"Gerst","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.cmet.2023.01.006_bib80","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1007\/s00125-021-05435-1","article-title":"The hepatokine fetuin-A disrupts functional maturation of pancreatic beta cells","volume":"64","author":"Gerst","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.cmet.2023.01.006_bib81","doi-asserted-by":"crossref","first-page":"818","DOI":"10.2337\/db17-1348","article-title":"Hepatic F-Box protein FBXW7 maintains glucose homeostasis through degradation of fetuin-A","volume":"67","author":"Zhao","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.cmet.2023.01.006_bib82","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/nm.3116","article-title":"Circulating fetuin-A and free fatty acids interact to predict insulin resistance in humans","volume":"19","author":"Stefan","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.cmet.2023.01.006_bib83","doi-asserted-by":"crossref","first-page":"e13183","DOI":"10.14814\/phy2.13183","article-title":"Interaction between plasma fetuin-A and free fatty acids predicts changes in insulin sensitivity in response to long-term exercise","volume":"5","author":"Lee","year":"2017","journal-title":"Physiol. Rep."},{"key":"10.1016\/j.cmet.2023.01.006_bib84","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1056\/NEJMc1412427","article-title":"Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease","volume":"371","author":"Stefan","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cmet.2023.01.006_bib85","doi-asserted-by":"crossref","first-page":"853","DOI":"10.2337\/diacare.29.04.06.dc05-1938","article-title":"Alpha2-heremans-schmid glycoprotein\/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans","volume":"29","author":"Stefan","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cmet.2023.01.006_bib86","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.1210\/jc.2008-1505","article-title":"Fetuin-A and its relation to metabolic syndrome and fatty liver disease in obese children before and after weight loss","volume":"93","author":"Reinehr","year":"2008","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.cmet.2023.01.006_bib87","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.metabol.2008.04.019","article-title":"Effects of pioglitazone on serum fetuin-A levels in patients with type 2 diabetes mellitus","volume":"57","author":"Mori","year":"2008","journal-title":"Metabolism"},{"key":"10.1016\/j.cmet.2023.01.006_bib88","doi-asserted-by":"crossref","first-page":"e88704","DOI":"10.1371\/journal.pone.0088704","article-title":"Direct inhibitory effects of pioglitazone on hepatic fetuin-A expression","volume":"9","author":"Ochi","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cmet.2023.01.006_bib97","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1172\/JCI17202","article-title":"The serum protein alpha 2-Heremans-Schmid glycoprotein\/fetuin-A is a systemically acting inhibitor of ectopic calcification","volume":"112","author":"Schafer","year":"2003","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.cmet.2023.01.006_bib98","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1006\/geno.1999.6041","article-title":"Identification of a mammalian angiopoietin-related protein expressed specifically in liver","volume":"62","author":"Conklin","year":"1999","journal-title":"Genomics"},{"key":"10.1016\/j.cmet.2023.01.006_bib99","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ng.3714","article-title":"Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance","volume":"49","author":"Lotta","year":"2017","journal-title":"Nat. Genet."},{"key":"10.1016\/j.cmet.2023.01.006_bib100","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1056\/NEJMe1706907","article-title":"Increasing lipolysis and reducing atherosclerosis","volume":"377","author":"Tall","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cmet.2023.01.006_bib101","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1097\/MEG.0b013e32832b77ae","article-title":"Serum concentrations of human angiopoietin-like protein 3 in patients with nonalcoholic fatty liver disease: association with insulin resistance","volume":"21","author":"Yilmaz","year":"2009","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.cmet.2023.01.006_bib102","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12944-021-01481-1","article-title":"Circulating angiopoietin-like proteins in metabolic-associated fatty liver disease: a systematic review and meta-analysis","volume":"20","author":"Ke","year":"2021","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.cmet.2023.01.006_bib105","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.cmet.2019.01.004","article-title":"A dozen years of discovery: insights into the physiology and pharmacology of FGF21","volume":"29","author":"Kliewer","year":"2019","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2023.01.006_bib106","doi-asserted-by":"crossref","first-page":"108893","DOI":"10.1016\/j.celrep.2021.108893","article-title":"FoxO1 suppresses Fgf21 during hepatic insulin resistance to impair peripheral glucose utilization and acute cold tolerance","volume":"34","author":"St\u00f6hr","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.cmet.2023.01.006_bib109","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1210\/er.2017-00016","article-title":"Fibroblast growth factor 21-metabolic role in mice and men","volume":"38","author":"Staiger","year":"2017","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.cmet.2023.01.006_bib112","article-title":"Fibroblast growth factor-based pharmacotherapies for the treatment of obesity-related metabolic complications","author":"Jin","year":"2022","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.cmet.2023.01.006_bib113","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.cmet.2022.03.005","article-title":"Deadenylase-dependent mRNA decay of GDF15 and FGF21 orchestrates food intake and energy expenditure","volume":"34","author":"Katsumura","year":"2022","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2023.01.006_bib114","first-page":"3979","article-title":"Monosaccharide-induced lipogenesis regulates the human hepatic sex\u00a0hormone-binding globulin gene","volume":"117","author":"Selva","year":"2007","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.cmet.2023.01.006_bib115","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1210\/me.2012-1152","article-title":"IL1beta down-regulation of sex hormone-binding globulin production by decreasing HNF-4alpha via MEK-1\/2 and JNK MAPK pathways","volume":"26","author":"Sim\u00f3","year":"2012","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.cmet.2023.01.006_bib116","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2337\/db11-0727","article-title":"Potential role of tumor necrosis factor-alpha in downregulating sex hormone-binding globulin","volume":"61","author":"Sim\u00f3","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.cmet.2023.01.006_bib117","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.tem.2015.05.001","article-title":"Novel insights in SHBG regulation and clinical implications","volume":"26","author":"Sim\u00f3","year":"2015","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.cmet.2023.01.006_bib118","doi-asserted-by":"crossref","first-page":"113261","DOI":"10.1016\/j.biopha.2022.113261","article-title":"Sex hormone binding globulin as a potential drug candidate for liver-related metabolic disorders treatment","volume":"153","author":"Bourebaba","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.cmet.2023.01.006_bib119","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1530\/EJE-16-0834","article-title":"Modulation of SHBG binding to testosterone and estradiol by sex and morbid obesity","volume":"176","author":"Grasa","year":"2017","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.cmet.2023.01.006_bib120","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.tem.2011.09.005","article-title":"Sex hormone-binding globulin and type 2 diabetes mellitus","volume":"23","author":"Le","year":"2012","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.cmet.2023.01.006_bib121","first-page":"545","article-title":"Sex hormone-binding globulin reduction in metabolic disorders may play a role in NAFLD development","volume":"158","author":"Saez-Lopez","year":"2017","journal-title":"Endocrinology"},{"key":"10.1016\/j.cmet.2023.01.006_bib122","doi-asserted-by":"crossref","first-page":"755","DOI":"10.3390\/cells10040755","article-title":"Sex hormone binding globulin (SHBG) mitigates ER stress in hepatocytes in\u00a0vitro and ex\u00a0vivo","volume":"10","author":"Kornicka-Garbowska","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.cmet.2023.01.006_bib123","doi-asserted-by":"crossref","first-page":"382","DOI":"10.5604\/01.3001.0009.8593","article-title":"Testosterone, sex hormone-binding globulin and nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"16","author":"Jaruvongvanich","year":"2017","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.cmet.2023.01.006_bib124","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1056\/NEJMc0910143","article-title":"Sex hormone-binding globulin and risk of type 2 diabetes","volume":"361","author":"Stefan","year":"2009","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cmet.2023.01.006_bib125","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.2337\/db10-0179","article-title":"Relationships of circulating sex hormone-binding globulin with metabolic traits in humans","volume":"59","author":"Peter","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.cmet.2023.01.006_bib129","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.cmet.2010.09.015","article-title":"A liver-derived secretory protein, selenoprotein P, causes insulin resistance","volume":"12","author":"Misu","year":"2010","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2023.01.006_bib130","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.mce.2013.09.013","article-title":"AMPK activator-mediated inhibition of endoplasmic reticulum stress ameliorates carrageenan-induced insulin resistance through the suppression of selenoprotein P in HepG2 hepatocytes","volume":"382","author":"Jung","year":"2014","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.cmet.2023.01.006_bib131","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1038\/s41467-017-01863-z","article-title":"Selenoprotein P-neutralizing antibodies improve insulin secretion and glucose sensitivity in type 2 diabetes mouse models","volume":"8","author":"Mita","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cmet.2023.01.006_bib132","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4093\/dmj.2013.37.1.63","article-title":"Increased selenoprotein p levels in subjects with visceral obesity and nonalcoholic fatty liver disease","volume":"37","author":"Choi","year":"2013","journal-title":"Diabetes Metab. J."},{"key":"10.1016\/j.cmet.2023.01.006_bib133","doi-asserted-by":"crossref","first-page":"8838","DOI":"10.3390\/ijms21228838","article-title":"Interplay between oxidative stress and metabolic derangements in non-alcoholic fatty liver disease: the role of selenoprotein P","volume":"21","author":"Caviglia","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cmet.2023.01.006_bib134","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1002\/jcp.30121","article-title":"SeP is elevated in NAFLD and participates in NAFLD pathogenesis through AMPK\/ACC pathway","volume":"236","author":"Chen","year":"2021","journal-title":"J.\u00a0Cell. Physiol."},{"key":"10.1016\/j.cmet.2023.01.006_bib135","doi-asserted-by":"crossref","first-page":"E1325","DOI":"10.1210\/jc.2011-0620","article-title":"Serum selenoprotein P levels in patients with type 2 diabetes and prediabetes: implications for insulin resistance, inflammation, and atherosclerosis","volume":"96","author":"Yang","year":"2011","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.cmet.2023.01.006_bib136","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.3390\/antiox11071263","article-title":"Associations between circulating SELENOP level and disorders of glucose and lipid metabolism: a meta-analysis","volume":"11","author":"Yu","year":"2022","journal-title":"Antioxidants"},{"key":"10.1016\/j.cmet.2023.01.006_bib138","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.cmet.2015.09.023","article-title":"Fetuin B is a secreted hepatocyte factor linking steatosis to impaired glucose metabolism","volume":"22","author":"Meex","year":"2015","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2023.01.006_bib139","first-page":"1498","article-title":"Fetuin B aggravates liver X receptor-mediated hepatic steatosis through AMPK in HepG2 cells and mice","volume":"11","author":"Zhou","year":"2019","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.cmet.2023.01.006_bib140","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.3390\/ijerph17082735","article-title":"Fetuin-A and Fetuin-B in non-alcoholic fatty liver disease: a meta-analysis and meta-regression","volume":"17","author":"Pan","year":"2020","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.cmet.2023.01.006_bib141","doi-asserted-by":"crossref","first-page":"E266","DOI":"10.1152\/ajpendo.00262.2017","article-title":"The hepatokines fetuin-A and fetuin-B are upregulated in the state of hepatic steatosis and may differently impact on glucose homeostasis in humans","volume":"314","author":"Peter","year":"2018","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.cmet.2023.01.006_bib142","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.mce.2016.06.002","article-title":"Circulating follistatin in relation to energy metabolism","volume":"433","author":"Hansen","year":"2016","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.cmet.2023.01.006_bib143","doi-asserted-by":"crossref","first-page":"5067","DOI":"10.1210\/jc.2004-0162","article-title":"Differential distribution of follistatin isoforms: application of a new FS315-specific immunoassay","volume":"89","author":"Schneyer","year":"2004","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.cmet.2023.01.006_bib144","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3233\/JND-150083","article-title":"Follistatin gene therapy improves ambulation in becker muscular dystrophy","volume":"2","author":"Al-Zaidy","year":"2015","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.cmet.2023.01.006_bib145","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1210\/en.2010-0868","article-title":"Exercise induces a marked increase in plasma follistatin: evidence that follistatin is a contraction-induced hepatokine","volume":"152","author":"Hansen","year":"2011","journal-title":"Endocrinology"},{"key":"10.1016\/j.cmet.2023.01.006_bib146","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1210\/jc.2015-3668","article-title":"Circulating follistatin is liver-derived and regulated by the glucagon-to-insulin ratio","volume":"101","author":"Hansen","year":"2016","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.cmet.2023.01.006_bib147","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2147\/DMSO.S159315","article-title":"Metabolic profiling of follistatin overexpression: a novel therapeutic strategy for metabolic diseases","volume":"11","author":"Singh","year":"2018","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"10.1016\/j.cmet.2023.01.006_bib148","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1038\/s41591-018-0129-0","article-title":"Publisher correction: inactivating hepatic follistatin alleviates hyperglycemia","volume":"24","author":"Tao","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.cmet.2023.01.006_bib149","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.tem.2010.02.008","article-title":"Emerging roles for the TGFbeta family in pancreatic beta-cell homeostasis","volume":"21","author":"Brown","year":"2010","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.cmet.2023.01.006_bib150","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1006\/dbio.2001.0555","article-title":"Follistatin regulates bone morphogenetic protein-7 (BMP-7) activity to stimulate embryonic muscle growth","volume":"243","author":"Amthor","year":"2002","journal-title":"Dev. Biol."},{"key":"10.1016\/j.cmet.2023.01.006_bib151","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.devcel.2005.09.008","article-title":"The structure of the follistatin:activin complex reveals antagonism of both type I and type II receptor binding","volume":"9","author":"Thompson","year":"2005","journal-title":"Dev. Cell"},{"key":"10.1016\/j.cmet.2023.01.006_bib152","doi-asserted-by":"crossref","first-page":"eaav5183","DOI":"10.1126\/scisignal.aav5183","article-title":"Specificity, versatility, and control of TGF-beta family signaling","volume":"12","author":"Derynck","year":"2019","journal-title":"Sci. Signal."},{"key":"10.1016\/j.cmet.2023.01.006_bib153","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1096\/fj.201802059RRR","article-title":"Intravascular follistatin gene delivery improves glycemic control in a mouse model of type 2 diabetes","volume":"34","author":"Davey","year":"2020","journal-title":"FASEB J."},{"key":"10.1016\/j.cmet.2023.01.006_bib154","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ymthe.2006.03.014","article-title":"Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8","volume":"14","author":"Inagaki","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.cmet.2023.01.006_bib155","doi-asserted-by":"crossref","first-page":"eaaz7492","DOI":"10.1126\/sciadv.aaz7492","article-title":"Gene therapy for follistatin mitigates systemic metabolic inflammation and post-traumatic arthritis in high-fat diet-induced obesity","volume":"6","author":"Tang","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.cmet.2023.01.006_bib157","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41591-020-1116-9","article-title":"Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes","volume":"27","author":"Wagner","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.cmet.2023.01.006_bib158","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.cell.2019.07.021","article-title":"LECT2, a ligand for Tie1, plays a crucial role in liver fibrogenesis","volume":"178","author":"Xu","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.cmet.2023.01.006_bib159","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.2337\/db13-0728","article-title":"LECT2 functions as a hepatokine that links obesity to skeletal muscle insulin resistance","volume":"63","author":"Lan","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.cmet.2023.01.006_bib160","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1530\/JME-17-0267","article-title":"LECT2 promotes inflammation and insulin resistance in adipocytes via P38 pathways","volume":"61","author":"Jung","year":"2018","journal-title":"J.\u00a0Mol. Endocrinol."},{"key":"10.1016\/j.cmet.2023.01.006_bib161","doi-asserted-by":"crossref","first-page":"e0173310","DOI":"10.1371\/journal.pone.0173310","article-title":"Visceral fat area is a strong predictor of leukocyte cell-derived chemotaxin 2, a potential biomarker of dyslipidemia","volume":"12","author":"Tanisawa","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.cmet.2023.01.006_bib162","doi-asserted-by":"crossref","first-page":"e0174717","DOI":"10.1371\/journal.pone.0174717","article-title":"Association of leukocyte cell-derived chemotaxin 2 (LECT2) with NAFLD, metabolic syndrome, and atherosclerosis","volume":"12","author":"Yoo","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.cmet.2023.01.006_bib163","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0167-4781(01)00249-4","article-title":"Molecular cloning and functional expression analysis of a cDNA for human hepassocin, a liver-specific protein with hepatocyte mitogenic activity","volume":"1520","author":"Hara","year":"2001","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.cmet.2023.01.006_bib164","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/gut.2008.171124","article-title":"Recombinant human hepassocin stimulates proliferation of hepatocytes in\u00a0vivo and improves survival in rats with fulminant hepatic failure","volume":"59","author":"Li","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.cmet.2023.01.006_bib165","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1210\/jc.2016-3287","article-title":"The hepatic protection effects of hepassocin in hyperglycemic crisis","volume":"102","author":"Ou","year":"2017","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.cmet.2023.01.006_bib166","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1007\/s00125-016-3991-7","article-title":"A novel hepatokine, HFREP1, plays a crucial role in the development of insulin resistance and type 2 diabetes","volume":"59","author":"Wu","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.cmet.2023.01.006_bib167","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.mce.2017.10.014","article-title":"Hyperlipidemia-induced hepassocin in the liver contributes to insulin resistance in skeletal muscle","volume":"470","author":"Jung","year":"2018","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.cmet.2023.01.006_bib168","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.jhep.2013.06.004","article-title":"The role of hepassocin in the development of non-alcoholic fatty liver disease","volume":"59","author":"Wu","year":"2013","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.cmet.2023.01.006_bib169","doi-asserted-by":"crossref","first-page":"eaaz8048","DOI":"10.1126\/scitranslmed.aaz8048","article-title":"SMOC1 is a glucose-responsive hepatokine and therapeutic target for glycemic control","volume":"12","author":"Montgomery","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cmet.2023.01.006_bib170","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.3390\/nu13124208","article-title":"Blood levels of the SMOC1 hepatokine are not causally linked with type 2 diabetes: a bidirectional mendelian randomization study","volume":"13","author":"Ghodsian","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.cmet.2023.01.006_bib171","doi-asserted-by":"crossref","first-page":"13267","DOI":"10.1038\/ncomms13267","article-title":"Control of diabetic hyperglycaemia and insulin resistance through TSC22D4","volume":"7","author":"Ekim \u00dcst\u00fcnel","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cmet.2023.01.006_bib172","doi-asserted-by":"crossref","first-page":"101487","DOI":"10.1016\/j.molmet.2022.101487","article-title":"Hepatocyte-specific activity of TSC22D4 triggers progressive NAFLD by impairing mitochondrial function","volume":"60","author":"Wolff","year":"2022","journal-title":"Mol. Metab."},{"key":"10.1016\/j.cmet.2023.01.006_bib173","doi-asserted-by":"crossref","first-page":"e129492","DOI":"10.1172\/jci.insight.129492","article-title":"The hepatokine Tsukushi is released in response to NAFLD and impacts cholesterol homeostasis","volume":"4","author":"Mouchiroud","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.cmet.2023.01.006_bib174","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s42255-018-0020-9","article-title":"The hepatokine Tsukushi gates energy expenditure via brown fat sympathetic innervation","volume":"1","author":"Wang","year":"2019","journal-title":"Nat. Metab."},{"key":"10.1016\/j.cmet.2023.01.006_bib175","doi-asserted-by":"crossref","first-page":"108987","DOI":"10.1016\/j.diabres.2021.108987","article-title":"Serum Tsukushi levels are elevated in newly diagnosed type 2 diabetic patients","volume":"178","author":"Li","year":"2021","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.cmet.2023.01.006_bib176","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1038\/s41467-020-15963-w","article-title":"Apolipoprotein J is a hepatokine regulating muscle glucose metabolism and insulin sensitivity","volume":"11","author":"Seo","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cmet.2023.01.006_bib177","doi-asserted-by":"crossref","first-page":"17484","DOI":"10.1038\/s41598-020-73927-y","article-title":"Clusterin overexpression protects against western diet-induced obesity and NAFLD","volume":"10","author":"Park","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cmet.2023.01.006_bib178","doi-asserted-by":"crossref","first-page":"612496","DOI":"10.3389\/fimmu.2021.612496","article-title":"Clusterin and its role in insulin resistance and the cardiometabolic syndrome","volume":"12","author":"Wittwer","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cmet.2023.01.006_bib179","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.3390\/biomedicines9121903","article-title":"Hepatokines and non-alcoholic fatty liver disease: linking liver pathophysiology to metabolism","volume":"9","author":"Kim","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.cmet.2023.01.006_bib180","doi-asserted-by":"crossref","first-page":"154261","DOI":"10.1016\/j.metabol.2020.154261","article-title":"FNDC4, a novel adipokine that reduces lipogenesis and promotes fat browning in human visceral adipocytes","volume":"108","author":"Fr\u00fchbeck","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.cmet.2023.01.006_bib181","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1038\/s41467-021-22579-1","article-title":"Orphan GPR116 mediates the insulin sensitizing effects of the hepatokine FNDC4 in adipose tissue","volume":"12","author":"Georgiadi","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cmet.2023.01.006_bib182","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1001\/jama.2012.94338","article-title":"Measures of adiposity and fat distribution and risk of diabetes--reply","volume":"309","author":"Neeland","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.cmet.2023.01.006_bib183","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1001\/jama.2012.94335","article-title":"Measures of adiposity and fat distribution and risk of diabetes","volume":"309","author":"Stefan","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.cmet.2023.01.006_bib184","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.mayocp.2021.08.021","article-title":"Cardiometabolic health outcomes associated with discordant visceral and liver fat phenotypes: insights from the dallas heart study and UK Biobank","volume":"97","author":"Tejani","year":"2022","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.cmet.2023.01.006_bib185","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat. Genet."},{"key":"10.1016\/j.cmet.2023.01.006_bib186","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S2213-8587(18)30051-2","article-title":"Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables","volume":"6","author":"Ahlqvist","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.cmet.2023.01.006_bib187","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.2337\/db22-0315","article-title":"Fat distribution patterns and future type 2 diabetes","volume":"71","author":"Yamazaki","year":"2022","journal-title":"Diabetes"},{"key":"10.1016\/j.cmet.2023.01.006_bib188","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1001\/archinte.168.15.1609","article-title":"Identification and characterization of metabolically benign obesity in humans","volume":"168","author":"Stefan","year":"2008","journal-title":"Arch. Intern. Med."}],"container-title":["Cell Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1550413123000062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1550413123000062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:43:09Z","timestamp":1761550989000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1550413123000062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":190,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S1550413123000062"],"URL":"https:\/\/doi.org\/10.1016\/j.cmet.2023.01.006","relation":{},"ISSN":["1550-4131"],"issn-type":[{"value":"1550-4131","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of hepatokines in NAFLD","name":"articletitle","label":"Article Title"},{"value":"Cell Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmet.2023.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}